Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer

NCT02228265 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT02228265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer
Lead sponsor
OHSU Knight Cancer Institute
Phase
Observational
Overall status
Completed
Start date
March 12, 2013
Completion date
February 27, 2020
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, prostate adenocarcinoma, psa progression, recurrent prostate carcinoma, stage iv prostate cancer